A phase I/II study of combined MEK and Bcl‐xL inhibition has shown initial signs of efficacy, with a favorable disease control rate and durable partial response in patients with RAS mutant gynecological cancer [47], demonstrating the clinical utility of the treatment strategy. The gene discussed is BCL2L1; the disease is female reproductive organ cancer.